Strofantin g ampoules of 0.25 mg 1 ml № 10

Solution for intravenous administration

Composition

1 ml of solution contains ouabain - 0.250 mg;
Excipients: citric acid, caustic soda, water for injection.

Packing

10 vials of 1 ml.

Mechanism of action

Strofantin-G is a cardiostimulating, antiarrhythmic agent that blocks the Na + / K + -ATPase of the cell membrane of cardiomyocytes. Increases the strength and speed of heart contractions (positive inotropic effect), reduces AV conduction (negative dromotropic effect), stimulates (in subtoxic and toxic doses) the formation of heterotropic pulses due to a decrease in the threshold of excitability and reduces heart rate (negative chronotropic effect).

Indications and usage

Acute heart failure or decompensated chronic heart failure, supraventricular tachycardia, atrial flutter and atrial fibrillation.

Contraindications

Glycosid intoxication, hypersensitivity to the active ingredient Strofantin-G.

Dosage and administration

Strofantin-G administered in / in, slowly. The dose is selected individually depending on the nosology and the patient's response to therapy. With an average rate of digitalization during the period of saturation, 250 μg are administered 2 times / day.with an interval of 12 hours. The duration of the saturation period is an average of 2 days. If necessary, you can enter an additional dose - 100-150 mcg with an interval of 0.5 to 2 h. The daily dose should not exceed 1 mg, which corresponds to 4 ml of solution for injection. The maintenance dose, as a rule, does not exceed 250 mcg / day.

Adverse reactions

Sometimes allergic reactions are possible. Other side effects are mainly due to an overdose of the drug or patient's hypersensitivity to cardiac glycosides.

With extreme caution used in patients with thyrotoxicosis and atrial extrasystole.
Given the low therapeutic breadth during treatment, careful medical observation and individual selection of the dose is necessary.
In case of violation of renal excretory function, the dose should be reduced (prevention of glycoside intoxication).
The likelihood of overdose increases with hypokalemia, hypomagnesemia, hypercalcemia, hypernatremia, severe dilatation of the heart cavities, pulmonary heart, alkalosis, in elderly patients. Special care and ECG monitoring are required when AV conduction is disturbed.

Drug interactions

Adrenostimulators, methylxanthines, reserpine, tricyclic antidepressants increase the likelihood of developing heart rhythm disturbances.
Beta-blockers and antiarrhythmic agents of the IA class, Verapamil and Magnesium sulfate increase the severity of AV conductivity reduction.
Quinidine, methyldopa, clonidine, spironolactone, Amiodarone, verapamil, Captopril, Erythromycin and Tetracycline increase blood concentration (a competitive decrease in secretion by the proximal tubules of the kidneys).
Glucocorticosteroids and diuretics increase the risk of hypokalemia and hypomagnesemia, angiotensin-converting enzyme (ACE) blockers and angiotensin receptors - reduce.
Calcium salts, catecholamines, diuretics (to a greater extent, thiazide and cartoanhydrase inhibitors), glucocorticosteroids, insulin increase the risk of glycoside intoxication.

Storage conditions

Store in a dark place, out of reach of children, at a temperature of from 15 to 25 ° C.